Clindamycin Hydrochloride
NDC 16590-057
View dosage, usage, ingredients, routes, and UNII mappings.
Product Information
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Clindamycin Hydrochloride is a ANDA-approved product labeled by Stat Rx Usa. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a blue product. This product entry covers the primary NDC 16590-057 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
16590-057
Proprietary Name:
Clindamycin Hydrochloride
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
16590
Product Label ID:
FDA Application Number: [6]
ANDA065061
Marketing Category: [8]
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Marketing Timeline
Start Marketing Date: [9]
02-02-2001
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I
Product Characteristics
Color(s):
BLUE (C48333 - BLUE (TURQUOISE BLUE) , GREEN (LIGHT GREEN) )
Shape:
CAPSULE (C48336)
Size(s):
19 MM
Imprint(s):
RX692
Score:
2
Code Structure Chart
Product Details
What is NDC 16590-057?
The NDC code 16590-057 is assigned by the FDA to the product Clindamycin Hydrochloride. This pharmaceutical product is labeled by Stat Rx Usa and is currently categorized as listed product. In terms of distribution, this product is available in 4 different package configurations. The associated package NDC(s) include: 16590-057-20, 16590-057-30, 16590-057-40, 16590-057-60. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
INDICATIONS AND USAGETo reduce the development of drug-resistant bacteria and maintain
the effectiveness of clindamycin hydrochloride capsules and other antibacterial
drugs, clindamycin hydrochloride capsules should be used only to treat or
prevent infections that are proven or strongly suspected to be caused by
susceptible bacteria. When culture and susceptibility information are available,
they should be considered in selecting or modifying antibacterial therapy. In
the absence of such data, local epidemiology and susceptibility patterns may
contribute to the empiric selection of therapy.Clindamycin is indicated in the treatment of serious infections caused by
susceptible anaerobic bacteria.Clindamycin is also indicated in the treatment of serious infections due to
susceptible strains of streptococci, pneumococci, and staphylococci. Its use
should be reserved for penicillin-allergic patients or other patients for whom,
in the judgment of the physician, a penicillin is inappropriate. Because of the
risk of colitis, as described in the WARNING box, before
selecting clindamycin the physician should consider the nature of the infection
and the suitability of less toxic alternatives (e.g., erythromycin).Anaerobes: Serious respiratory tract infections such
as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue
infections; septicemia; intra-abdominal infections such as peritonitis and
intra-abdominal abscess (typically resulting from anaerobic organisms resident
in the normal gastrointestinal tract); infections of the female pelvis and
genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic
cellulitis and postsurgical vaginal cuff infection.Streptococci: Serious respiratory tract infections;
serious skin and soft tissue infections.Staphylococci: Serious respiratory tract infections;
serious skin and soft tissue infections.Pneumococci: Serious respiratory tract
infections.Bacteriologic studies should be performed to determine the causative
organisms and their susceptibility to clindamycin.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W)
- CLINDAMYCIN (UNII: 3U02EL437C) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 197518 - clindamycin HCl 150 MG Oral Capsule
- RxCUI: 197518 - clindamycin 150 MG Oral Capsule
- RxCUI: 197518 - clindamycin (as clindamycin HCl) 150 MG Oral Capsule
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".